Top 5 Papers
#1
Source: JAMA Oncology | Authors: Ong M, He K, Wang F, et al. (Zhejiang University, Renji Hospital, Sun Yat-sen University and 5 further Chinese transplant centres) | Published: October 1, 2026
Score: 10/20 — Base 7 (JAMA Oncology) + 1 (retrospective propensity-matched cohort) + 2 (survival benefit — adjusted OS HR 0.63 and RFS HR 0.59) = 10. No colleague-engagement bonus: the X sweep ran all 6 curated handles this edition and surfaced no qualifying post for this paper.
Downstaging HCC that sits outside the Milan criteria into transplantability is one of the most consequential decisions in liver oncology, and whether checkpoint inhibitors belong in that pathway has been unresolved — partly because of a genuine fear of precipitating graft rejection. This multicentre retrospective cohort drew on 8 high-volume Chinese transplant centres (>55 liver transplants annually) between January 2019 and December 2024 and propensity-matched 416 recipients, 208 who received an ICI-based multimodal pretransplant strategy (typically with locoregional and/or targeted therapy) and 208 who did not. Median overall survival from transplant was 4.57 years (95% CI 4.34 to not estimable) with ICIs versus 2.53 years (95% CI 2.17-3.10) without, P < .001, and median recurrence-free survival 1.47 versus 0.89 years, P = .02. Multivariable Cox models gave an OS HR of 0.63 (95% CI 0.43-0.92) and an RFS HR of 0.59 (95% CI 0.44-0.80), with a Fine-Gray subdistribution HR of 0.54 (95% CI 0.40-0.72) for post-transplant recurrence. The safety signal is real and should not be buried: acute rejection within 90 days occurred in 16.3% (34/208) of the ICI group versus 8.2% (17/208), P = .01. The cohort was 90.6% male with a median age of 53 — a hepatitis-B-dominant population whose generalisability to Western MASH-driven HCC is unproven, and the design cannot exclude residual confounding by who was offered ICIs in the first place.
Post angle: ICI-based downstaging before liver transplant in HCC beyond Milan: median OS 4.57 vs 2.53 years across 416 matched recipients — with acute rejection doubling. The efficacy case is now hard to ignore; the rejection trade-off is the real conversation. #GIOnc #HCC #LiverTransplant #Immunotherapy
#2
Source: Gut | Authors: Maddalena G, Aziz K, Sun R, et al. (MD Anderson Cancer Center; Veneto Institute of Oncology) | Published: October 1, 2026
Score: 9/20 — Base 7 (Gut) + 1 (prospective observational real-world cohort) + 1 (biomarker-guided / precision) = 9. No colleague-engagement bonus: the X sweep ran all 6 curated handles and surfaced no qualifying post for this paper.
INTERCEPT is a prospective observational cohort of stage II-IV colorectal cancer patients treated with curative intent and monitored longitudinally with tissue-informed ctDNA assays as part of routine care — which makes it a read on what MRD testing actually does to practice, not just on whether it predicts. The headline finding reorders something clinicians treat as fixed: MRD-positive stage II-III patients had a higher recurrence incidence than MRD-negative stage IV patients (p<0.0001), and the prognostic value persisted beyond 12 months from surgery rather than decaying. Multi-timepoint testing raised sensitivity for recurrence to 79.9% from 48.5% with single-timepoint testing, which is the most directly actionable number here. Two findings deserve more attention than they will get. Adjuvant therapy in stage IV disease showed limited durable benefit in MRD-positive and MRD-negative patients alike — detecting MRD is not the same as having something that works against it. And concurrent macroscopic disease was already present in 26% of cases at the moment ctDNA was detected, so the true lead time is smaller than raw numbers imply and varies across surveillance (p=0.007). ctDNA detection also drove more intensive second-line imaging (MRI, PET; p<0.0001). The authors are explicit that interventional trials are still required to establish clinical utility.
Post angle: The INTERCEPT number that should change how we talk about staging: MRD-positive stage II-III colorectal cancer recurs more often than MRD-negative stage IV. And multi-timepoint ctDNA nearly doubles sensitivity, 79.9% vs 48.5%. Detection still outpaces what we can do about it. #GIOnc #CRC #ctDNA #MRD
#3
Source: JCO Precision Oncology | Authors: Loree JM, Titmuss E, Brown CJ, et al. (Canadian Cancer Trials Group CO.28) | Published: October 2, 2026
Score: 9/20 — Base 6 (JCO Precision Oncology) + 2 (correlative analysis of a Phase II trial) + 1 (biomarker-guided / precision) = 9. No colleague-engagement bonus: the X sweep ran all 6 curated handles and surfaced no qualifying post for this paper.
Organ preservation in early rectal cancer turns on one question: who can safely skip total mesorectal excision. This correlative study of the Canadian Cancer Trials Group NEO trial (CO.28) tested whether a tissue-free assay can help answer it, analysing 53 of 58 trial patients (91.4%) with the Guardant Reveal epigenomic assay across pre-chemotherapy, post-chemotherapy/pre-transanal endoscopic surgery, and follow-up at 12, 24 and 36 months. ctDNA was detected in 45.8% of patients before neoadjuvant chemotherapy, with detection similar across T-stage (p=.18), then fell sharply to 8.7% after chemotherapy and before surgery (p<.0001); 41.4% of evaluable patients converted from detectable to completely undetectable. Post-chemotherapy ctDNA tracked with poor response and persistent cancer (p=.03): TME was recommended for 100% of ctDNA-positive patients versus 38.1% (16/42) of ctDNA-negative patients. The ceiling on this result is the denominator, and it is severe — that 100% is 4 of 4 patients. Five recurrences occurred during follow-up (two local, three distant), and of the two local recurrences with longitudinal plasma, one had detectable ctDNA at progression. The appeal of a tissue-free assay is turnaround time versus tumour-informed approaches, which matters when a surgical decision is waiting on it. This is hypothesis-generating, not a decision rule.
Post angle: NEO/CO.28 ctDNA: detection fell 45.8% to 8.7% after neoadjuvant chemo, and post-chemo ctDNA positivity sent 100% of those patients to TME vs 38.1% of ctDNA-negative. Read the denominator before you adopt it — that 100% is 4 of 4. Promising signal, not a decision rule. #GIOnc #RectalCancer #ctDNA
#4
Source: Clinical Cancer Research | Authors: Pappas L, Koenig JL, Yeap BY, et al. (Massachusetts General Hospital; Dana-Farber Cancer Institute) | Published: October 1, 2026
Score: 8/20 — Base 6 (Clinical Cancer Research) + 2 (Phase II) + 0 (clinical impact) = 8. No clinical-impact bonus is awarded deliberately: the confirmed ORR was 10.0% and median PFS 2.4 months, so there is no survival benefit to credit, and the liver-metastasis contrast is an underpowered post-hoc subgroup rather than a validated selection biomarker. Scoring the evidence rather than the framing. No colleague-engagement bonus: the X sweep ran all 6 curated handles and surfaced no qualifying post for this paper.
The idea that radiation can prime microsatellite-stable colorectal cancer to respond to checkpoint blockade has been attractive for years and keeps underdelivering. This multi-institution, open-label, single-arm Phase II enrolled 30 patients with MSS metastatic colorectal cancer previously treated with oxaliplatin, 5-fluorouracil and irinotecan, giving non-ablative immune-modulating radiotherapy with nivolumab and ipilimumab. The primary endpoint, confirmed objective response rate in unirradiated lesions, was 10.0%, with a disease control rate of 33.3%; irradiated lesions showed an ORR of 13.3% and DCR of 83.3%, which mostly reflects local radiation effect rather than systemic immunity. Median PFS was 2.4 months at a median follow-up of 19.8 months and median OS 12.8 months (95% CI 6.8-17.9). Tolerability was acceptable, with grade 4 toxicity in 10% of patients, lymphopenia in every case. The most quoted number will be the subgroup split: ORR 25.0% (95% CI 3.2-65.1) in the 8 patients without active liver metastases versus 4.6% (95% CI 0.1-22.8) in the 22 with them. Those confidence intervals overlap and span almost the entire possible range, so this confirms a now-familiar pattern — hepatic metastases as a site of immune resistance in colorectal cancer — rather than establishing a selection rule. A negative trial that is still worth reading for where the next one should enrol.
Post angle: Radiation plus nivo-ipi in refractory MSS colorectal cancer: confirmed ORR 10.0%, median PFS 2.4 months. The liver-metastasis split (25.0% vs 4.6%) is the talking point, but n=8 vs 22 with CIs that overlap almost entirely. Negative trial, useful signal about where to enrol next. #GIOnc #CRC #Immunotherapy
#5
Source: Endoscopy | Authors: Lee Y, Song TJ, Kim S, et al. (Asan Medical Center, Seoul) | Published: October 2, 2026
Score: 8/20 — Base 5 (Endoscopy) + 1 (retrospective cohort) + 2 (survival benefit — adjusted HR 0.34 for 6-month mortality with early ablation) = 8. The +2 is awarded on the early-window estimate only; the full-follow-up association attenuated to aHR 0.77 (P=0.209) after adjustment for calendar year, and that caveat is carried in the summary rather than scored away. No colleague-engagement bonus: the X sweep ran all 6 curated handles and surfaced no qualifying post for this paper.
Endobiliary radiofrequency ablation is widely offered in unresectable perihilar cholangiocarcinoma on fairly thin survival evidence, and this retrospective cohort of 475 patients treated with endoscopic biliary drainage at Asan Medical Center between 2015 and 2025 is an unusually careful attempt to pin down whether and when it helps. Ninety patients had a single RFA session and 50 had two or more, and crucially RFA was modelled as a time-dependent cumulative count with landmark analyses of subsequent 6-month mortality at baseline and at 3, 6, 9 and 12 months — the design choice that separates a real effect from immortal-time artefact. RFA performed within 7 days of drainage was associated with lower 6-month mortality, adjusted HR 0.34 (95% CI 0.16-0.70, P=0.004). At the 3-month landmark, two or more sessions were associated with lower mortality (aHR 0.10, P=0.024), with no association at any later landmark. Across the entire follow-up, two or more sessions looked protective (aHR 0.59, P=0.007) but that association attenuated to non-significance once calendar year was accounted for (aHR 0.77, P=0.209) — a reminder that a decade-long series also captures a decade of improving systemic therapy. The cost side is concrete: recurrent biliary obstruction was more frequent after RFA, 37.9% versus 22.1% (P<0.001), with the excess confined to non-tumour causes. The practical reading is that timing, not cumulative dose, is what the data support.
Post angle: 475 unresectable perihilar cholangiocarcinomas: endobiliary RFA within 7 days of drainage was associated with lower 6-month mortality, aHR 0.34. The benefit concentrates in the first 3 months and the full-follow-up effect vanishes after adjusting for calendar year. Timing over cumulative dose. #GIOnc #Cholangiocarcinoma #Endoscopy
Additional Papers of Interest
-
British Journal of Cancer — Prospective observational study of 468 patients with metastatic colorectal cancer scheduled for later-line therapy (regorafenib n=154; FTD/TPI n=82; FTD/TPI plus bevacizumab n=232); after inverse-probability-of-treatment weighting, median OS was 12.2 vs 10.6 months, HR 1.03, 95% CI 0.81-1.30, P=0.837, so sequence choice should follow the distinct grade ≥3 toxicity profiles — hand-foot syndrome, proteinuria and hypertension with regorafenib versus neutropenia and anaemia with FTD/TPI.
-
Clinical Cancer Research — Serial ctDNA in biliary tract cancer (39 baseline, 30 at progression) implicated baseline MET SNVs and ERBB2 CNVs in primary resistance, while rising EGFR and MET copy-number scores during treatment tracked markedly worse outcomes (EGFR: TTP 4.1 vs 9.5 months, OS 10.1 vs 21.6 months); matched radiomic features correlated with the molecular escape route.
-
European Journal of Cancer — Netherlands Cancer Registry target-trial emulation of 7,380 patients with metastatic oesophagogastric adenocarcinoma; among 2,812 prognostically favourable patients eligible for either strategy, starting systemic therapy after 8 weeks versus within 8 weeks gave median OS 10.9 vs 9.4 months, HR 0.91, 95% CI 0.82-1.02, with comparable quality of life and some signal of better social and role functioning and less fatigue at 3 months in the deferred group.
-
BJS Open — Exploratory analysis of the Ultimate trial, a prospective Phase II study across 47 Japanese institutions; among 297 patients with cT1-2 N0 ultra-low rectal cancer, 3-year local recurrence was 11.9% for anterior versus 3.0% for non-anterior tumours, HR 4.46, 95% CI 1.67-11.89, P=0.001, with the excess confined to cT2 disease, 25.3% vs 4.7%, and no difference in cT1.
-
Nature Communications — GLOBOCAN 2022 and CI5-based analysis of esophageal cancer by histology and anatomical third: squamous cell carcinoma peaks in Eastern Asia (ASR 7.2 per 100,000) alongside upper- and middle-third disease (6.0) and is declining overall, while adenocarcinoma peaks in Northern Europe (3.2) alongside lower-third disease (3.6) and is rising, with the two groups carrying distinct risk-factor profiles that argue for region-specific prevention.
Back to all digests